EURASIAN JOURNAL OF PULMONOLOGY, cilt.17, sa.1, ss.49-53, 2015 (ESCI, TRDizin)
Objective: Concomitant chemoradiotherapy (CRT) is the standard treatment for patients with stage III non-small cell lung cancer (NSCLC). Myelosuppression can be a significant problem in concomitant CRT. The aim of this study was to assess the parameters obtained before concomitant CRT to define the risk factors for myelosuppression in patients with locally advanced NSCLC.